Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Fagron: Q1 2026 sales exceed expectations, margins remain under pressure

Fagron reports Q1 2026 sales of €263.4m (+10.3% yoy; organic +3.2% CER), driven by strong performance in Latin America and M&A contributions. Management sees short-term margin pressure from dilutive effects of recent acquisitions and normalization of GLP-1 sales in North America. For 2026 Fagron expects organic growth in the mid to high single digits (CER) and an REBITDA margin of around 20%, with synergies expected to raise the margin to about 21% by 2027. The stock dipped slightly after the results were released. » Mere på de.investing.com
Fagron posts record result in 2025: organic growth 9.1% and rising REBITDA margin

Fagron achieved revenue of €952.2m in 2025 (+9.2%) and organic growth of 9.1% at constant exchange rates. REBITDA increased by 10.9% to €192.9m with a margin of 20.3%, and free cash flow climbed 29% to €125.9m. The net leverage ratio fell to 1.2x despite 12 completed acquisitions that strategically strengthen growth and market position. For 2026 Fagron expects mid- to high-single-digit organic growth and a slight margin improvement, but sees risks from currency effects, supply chains and integration tasks. » Mere på de.investing.com
Fagron buys companies in Singapore/Malaysia and Brazil and strengthens APAC and packaging business

Fagron has announced two acquisitions: a business for non-sterile compounding prescription medicines in Singapore and Malaysia and Vepakum in Brazil (packaging manufacturing). The two targets together generate around €26m in revenue and €6.7m EBITDA (EBITDA margin 26%). The purchase price is €55m, equivalent to an entry multiple of about 8x EV/EBITDA; pro forma the acquisitions increase annual revenue by around 3% and Fagron’s EBITDA by about 4%. The transactions will be financed from existing funds and are expected to raise the net leverage ratio only marginally by about 0.2 percentage points; the initial multiple effect is estimated at 1–2% of market capitalization. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2026 har Fagron allerede udloddet 0,40 € i udbytte. Den seneste udlodning fandt sted i maj.

Virksomhedstal

I det seneste kvartal havde Fagron en omsætning på 551,66 mio. € og et nettoresultat på 46,21 mio. €

(EUR)	juni 2026	YoY
Omsætning	551,66 mio.	-
Bruttofortjeneste	111,01 mio.	-
Nettoresultat	46,21 mio.	-
EBITDA	102,81 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	1,75 mia. €
Antal aktier	73,35 mio.
Højeste/laveste i 52 uger	24,18 € - 20,37 €
Udbytteafkast	1,92 %
Udbytte TTM	0,40 €
Beta	0,39
P/E (PE Ratio)	16,80
PEG (PEG Ratio)	2,46
K/I (PB Ratio)	2,59
P/S (PS Ratio)	1,50

Virksomhedsprofil

Fagron NV, ein pharmazeutisches Compounding-Unternehmen, bietet Krankenhäusern, Apotheken, Kliniken und Patienten personalisierte medizinische Versorgung an. Das Unternehmen entwickelt außerdem innovative Konzepte, Fahrzeuge und Formulierungen für die pharmazeutische Herstellung von Arzneimitteln. Darüber hinaus liefert das Unternehmen Rohstoffe, Geräte und Ausrüstungen, Halbfertigprodukte, Fahrzeuge sowie sterile und unsterile Compounding-Medikamente. Darüber hinaus bietet das Unternehmen über die Fagron Academy Schulungs- und Trainingsprogramme für Verschreiber und Apotheker an. Das Unternehmen ist in Lateinamerika, Nordamerika, Europa, dem Nahen Osten und Afrika tätig. Das Unternehmen war früher unter dem Namen Arseus NV bekannt und änderte im Januar 2015 seinen Namen in Fagron NV. Fagron NV wurde 1990 gegründet und hat seinen Sitz in Nazareth, Belgien.